Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Three-part, Phase 1, Single-ascending, and Multiple-ascending Dose Escalation Study in Healthy Volunteers and Subjects With Systemic Amyloidosis to Assess the Safety, Tolerability, and Pharmacokinetics of AT-02

Next Previous
X
Search
Trial Profile

A Three-part, Phase 1, Single-ascending, and Multiple-ascending Dose Escalation Study in Healthy Volunteers and Subjects With Systemic Amyloidosis to Assess the Safety, Tolerability, and Pharmacokinetics of AT-02

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 07 Apr 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs AT-02 (Primary)
  • Indications Amyloidosis
  • Focus Adverse reactions
  • Acronyms AT02-001
  • Sponsors Attralus

    • Most Recent Events

    • 02 Apr 2024 Planned End Date changed from 1 Mar 2024 to 1 Mar 2025.
    • 02 Apr 2024 Planned primary completion date changed from 1 Mar 2024 to 1 Mar 2025.
    • 06 Feb 2024 According to Attralus media release, company announced that it has closed a $56 million financing. Attralus intends to use the proceeds from the financing to advance the Phase 1/2 development of AT-02, in ATTR and AL amyloidosis.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top